AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03926689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard SII SBCC
Description: Home visits/IPC; community events including food demo and key life events; and Bhanchhin Aama radio program episodes
Study NCT03101774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold inspiratory muscle training
Description: Threshold inspiratory muscle training device (Threshold Inspiration Muscle Trainer, Respironics Inc; Pittsburgh, Pennsylvania, USA). The intensiy of IMT was adjusted and verification using Pm measurement in laboratory. Patients spontaneously breathed using resistive-IMT and their Pm were measured simultaneously. Adjusted the intensity of resistive-IMT from small to large according to the Pm waveform. Adjustment completed while mean Pm achieved 60% of MIP and maintained at least 15 minute. Likewise, eligible patients in these group used the resistive IMT device for 15 minutes, twice per day, with an inspiratory load at 60% of PImax as previously adjustment. Training loads were adjusted to maintain 60% of the PImax every week.
Study NCT03101774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resistive inspiratory muscle training
Description: Resistive inspiratory muscle training device(PFLEX, Respironics Inc; Pittsburgh, Pennsylvania, USA). The intensiy of IMT was adjusted and verification using Pm measurement in laboratory. Patients spontaneously breathed using resistive-IMT and their Pm were measured simultaneously. Adjusted the intensity of resistive-IMT from small to large according to the Pm waveform. Adjustment completed while mean Pm achieved 60% of MIP and maintained at least 15 minute. Likewise, eligible patients in these group used the resistive IMT device for 15 minutes, twice per day, with an inspiratory load at 60% of PImax as previously adjustment. Training loads were adjusted to maintain 60% of the PImax every week.
Study NCT03101774 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: Conventional therapy without any inspiratory muscle training program
Study NCT01166503 — intervention group
Intervention type: PROCEDURE
Intervention: mVEP Testing
Description: Five small sensors are placed on the head which record the brain's response to moving stripes that are displayed on a computer screen. Each eye is tested while the other eye is patched. Each recording trial lasts about 10 seconds, and several trials are done for each eye.
Study NCT01166503 — intervention group
Intervention type: PROCEDURE
Intervention: Stereoacuity Testing
Description: Subjects will have their 3D perception measured using standard clinical stereo tests (Randot, Lang, Titmus).
Study NCT01166503 — intervention group
Intervention type: PROCEDURE
Intervention: Optokinetic nystagmus testing
Description: Subjects will be asked to view a screen with vertical stripes moving in both leftward and rightward directions while their eye movements are recorded using a remote video-based eye tracker.
Study NCT01166503 — intervention group
Intervention type: PROCEDURE
Intervention: Motion detection testing
Description: Subjects will view a computer screen that has two panels of dots on them. The subject will be required to pick which panel has a section of dots that are moving in a specific direction (ie. nasalward/temporalward).
Study NCT01166503 — intervention group
Intervention type: PROCEDURE
Intervention: Motion discrimination testing
Description: Subjects will view a computer screen that has two panels of randomly moving dots on them. The subject will be required to pick which panel has a section of dots that are moving in a specific direction (ie. nasalward/temporalward).
Study NCT04623203 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT00102960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir sulfate
Description: Second Line Regimen: 8 mg/kg taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.
Study NCT00102960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Didanosine
Description: Second Line Regimen: Either 100 mg/m\^2 or 120 mg/m\^2 taken orally twice daily. Dosage depends on age. Guidelines for switching from first line to second line therapy are available in the protocol.
Study NCT00102960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Second Line Regimen: taken orally once daily. Dosage depends on weight. Guidelines for switching from first line to second line therapy are available in the protocol.
Study NCT00102960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: First Line Regimen: 4 mg/kg taken orally twice daily
Study NCT00102960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: First Line Regimen: taken orally twice daily. Dosage depends on age and weight.
Study NCT00102960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: Second Line Regimen: 150 - 200 mg/m\^2 taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.
Study NCT00102960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: First Line Regimen: 240 mg/m\^2 taken orally twice daily
Study NCT03246139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action observation, imagery & execution
Description: The participants will be asked to observe movements through a video clip, practice motor imagery, and executing the movements that the participants observed.
Study NCT03246139 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Action observation
Description: The participants will be asked to observe videos and then practice what the participants observed.
Study NCT03246139 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control treatment
Description: The participants will receive UE training without watching videos or imagining movements/tasks.
Study NCT03721510 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PGT121 + VRC07-523LS
Description: PGT121 + VRC07-523LS, dose 30 mg/kg each, given intravenously
Study NCT03721510 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PGT121 + VRC07-523LS + PGDM1400
Description: PGT121 + VRC07-523LS + PGDM1400, dose 20 mg/kg each, given intravenously
Study NCT02047539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 1000 mg/day of aspirin 1000 mg/day of sugar pill
Study NCT02047539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04358263 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring Guardian Connect Mobile system (real-time continuous glucose monitoring)
Description: rtCGM and isCGM are used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.
Study NCT04358263 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring FreeStyle Libre Flash system (intermittently-scanned continuous glucose monitoring)
Description: rtCGM and isCGM are used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.
Study NCT03404089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pharmacokinetic device
Description: MON4STRAT system: bed-side pharmacokinetic device for drug concentration measurement
Study NCT03404089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pharmacokinetic device
Description: High performance liquid chromatography, (HPLC), the reference methods HLPC tandem mass spectrometry or Ultraviolet are using
Study NCT01194453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin, dexamethasone,vitamin B12, folic acid
Description: Patients received cisplatin 75mg/m2 plus pemetrexed 500 mg/m2 on day 1.Chemotherapy was repeated every 3 weeks for a maximum of six cycles.Patients received dexamethasone prophylaxis of 3.75mg orally twice per day on the day before, the day of, and the day after each day-1 treatment. patients received oral folic acid (1,000ug)daily and a vitamin B12 injection (1,000 ug) every 9 weeks, beginning 1 to 2 weeks before the first dose and continuing until 3 weeks after the last dose of study treatment
Study NCT01194453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin, gemcitabine
Description: cisplatin 75mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8
Study NCT03202823 — intervention group
Intervention type: PROCEDURE
Intervention: blood samples
Description: 3 tubes (5 ml volume) collected during surgery
Study NCT03202823 — intervention group
Intervention type: PROCEDURE
Intervention: recover samples of atheromatous plaque
Description: a carotid sample collected during surgery
Study NCT04828187 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Comparison of the proposed artificial network with the ground truth
Description: Both eyes will be included for each study participant. Participants watched a 4-10-minute video in standard mesopic environmental lighting conditions at 3.5m viewing distance. Simultaneously, all blinking moves will be recorded through a web infrared camera.~The proposed system was tested on the 8 different subjects. Several metrics of blink detection and classification accuracy were calculated against the ground truth, which was generated by 3 independent experts, whose conflicts were resolved by a senior expert. Two independent blink identifications are assumed to be in agreement, if and only if there is sufficient temporal overlapping and the type of blink is the same between the DLED system and the ground truth.
Study NCT01837069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: 25mg PO BID if the HR is elevated at preadmission testing
Study NCT01837069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: 2.5mg PO QD if the HR is elevated at preadmission testing
Study NCT01837069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 80mg PO QD at preadmission testing
Study NCT01837069 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counseling
Description: Diet, exercise, medication adherance and smoking counseling
Study NCT02217436 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPad
Description: iPad with age-appropriate applications, videos, and music
Study NCT02217436 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: All study participants will receive standard care, which consists of procedural explanation and preparation by providers, verbal encouragement and comforting by providers and parents, and topical anesthetic (LET) followed by injectable lidocaine administration (whether one or both of these anesthetics will be used will be determined by the provider prior to randomization).
Study NCT02217436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: All study participants will receive standard care, which consists of procedural explanation and preparation by providers, verbal encouragement and comforting by providers and parents, and topical anesthetic (LET) followed by injectable lidocaine administration (whether one or both of these anesthetics will be used will be determined by the provider prior to randomization).
Study NCT03974399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Bacopa Monnieri
Description: subjects will take Bacopa Monnieri daily for 3 months
Study NCT04612036 — intervention group
Intervention type: DEVICE
Intervention: Journey II Bi-Cruciate Stabilized TKA
Description: Total Knee Arthroplasty System
Study NCT04612036 — intervention group
Intervention type: DEVICE
Intervention: Journey II Cruciate Retaining TKA
Description: Total Knee Arthroplasty System
Study NCT04612036 — intervention group
Intervention type: DEVICE
Intervention: Journey II Bi-Cruciate Retaining TKA
Description: Total Knee Arthroplasty System
Study NCT02020057 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty
Description: Total knee arthroplasty with standard incision and approach, and cement fixation. Zimmer Nexgen posterior stabilized total knee implants are used.
Study NCT02020057 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty
Description: Total knee arthroplasty with standard incision and approach, and cement fixation. Zimmer Nexgen posterior stabilized total knee implants are used.
Study NCT00437502 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tumor peptide vaccine
Description: Cohort 1 low dose level of vaccine @ 0.3 mg administered as x1 weekly injection given intradermally/subcutaneously into site assigned( same limb) for total number of study vaccine injections = 6.
Study NCT00437502 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tumor peptide vaccine
Description: Cohort 2 high dose vaccine @ 1 mg administered as x1 weekly injection given intradermally/subcutaneously into site assigned( same limb) for total number of study vaccine injections = 6.
Study NCT04641299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8233
Description: PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
Study NCT04641299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution
Study NCT00311376 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A (200U)
Description: botulinum toxin Type A 200 U (tx 1) followed by botulinum toxin Type A 200 U (tx 2); injections into detrusor, at > 12 weeks interval
Study NCT00311376 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A (300U)
Description: botulinum toxin Type A 300 U (tx 1) followed by botulinum toxin Type A 300 U (tx 2); injections into detrusor, at > 12 weeks interval
Study NCT00311376 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Normal Saline (Placebo); botulinum toxin Type A (200U)
Description: Placebo (tx 1) followed by botulinum toxin Type A 200 U (tx 2); injections into detrusor, at > 12 weeks interval
Study NCT00311376 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Normal Saline (Placebo); botulinum toxin Type A (300U)
Description: Placebo (tx 1) followed by botulinum toxin Type A 300 U (tx 2), injections into detrusor, at > 12 weeks interval
Study NCT03419039 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anthocyanins
Description: Medox tablet containing 80 mg anthocyanins.
Study NCT03419039 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically appearing capsules.
Study NCT02791282 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Index test: functional dynamic contrast enhanced (DCE)-MRI
Description: Index test: functional dynamic contrast enhanced (DCE)-MRI Reference test: Ventilation-perfusion (VQ) single-photon emission computed tomography (SPECT) Follow-up per patient: clinical assessment after 6-12 months
Study NCT02198339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBN 4096 BS
Study NCT02198339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01805596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Study NCT01805596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Study NCT04175106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a non-traditional (i.e., not typically available in the supermarket) blueberry cultivar bred using natural plant breeding techniques and established as having enhanced nutritive value
Description: 150 g of a non-traditional (i.e., not typically available in the supermarket) blueberry cultivar bred using natural plant breeding techniques and established as having enhanced nutritive value.~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days.
Study NCT04175106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a standard commercially available blueberry variety (i.e., cultivar)
Description: 150 g of a standard commercially available blueberry variety (i.e., cultivar).~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days.
Study NCT04175106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a minimally processed blueberry-rich protein bar
Description: A minimally processed blueberry-rich protein bar matched to the phytonutrient content of the 150 g of the non-traditional blueberry.~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days.
Study NCT04175106 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: a control beverage of matched-nutritive content
Description: The matched nutritive content of the blueberry-rich protein bar will be dissolved in whey protein~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days.
Study NCT00613353 — intervention group
Intervention type: OTHER
Intervention: Behavioral
Description: Participants will be asked to wear an accelerometer
Study NCT01817907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Subjects will receive a sugar pill during the placebo arm
Study NCT01817907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: Subjects will receive trazodone during one of their treatment arm studies
Study NCT03380351 — intervention group
Intervention type: BEHAVIORAL
Intervention: SCDIC interventions
Description: The research team will characterize the intervention components and their implementation strategies.
Study NCT02761824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Camp Discovery
Description: Activities included physical, social, emotional, sensory and spiritual activities.
Study NCT03580239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus will be treated at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days. The patients also receive the best supportive care.
Study NCT03580239 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be treated at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days. The patients also receive the best supportive care.
Study NCT02608060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Beta
Description: Dosage at Initiation: Subcutaneous injection of 30000 IU administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 g/dL versus baseline.
Study NCT02170675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Study NCT02170675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Study NCT03611283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouthwash treatment
Description: 60 seconds after meals (3 times/day) during 28 days
Study NCT03611283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toothpaste treatment
Description: 3 minutes after the mouthwash (3 times/day) during 28 days
Study NCT03611283 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mouthwash placebo
Description: 60 seconds after meals (3 times/day) during 28 days
Study NCT03611283 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Toothpaste placebo
Description: 3 minutes after the mouthwash (3 times/day) during 28 days
Study NCT03662672 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rib raising and lumbar release
Description: Rib raising per protocol described in arm description.
Study NCT03662672 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Sham procedure per protocol described in arm description
Study NCT01971983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-velocity, low-amplitude (HVLA)
Description: With the subject lying on his/her side, the therapist will rotate the patient's trunk, flex his/her hip and knee of the upper leg. The therapist positions his caudad forearm over the hip, while the cephalad forearm lies over the patient's shoulder. The therapist's hands will be positioned over the lumbar spine's spinous process to be manipulated.
Study NCT01971983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle energy (ME)
Description: This technique involves the active movement of the patient to activate a specific musculature in order to move a bony segment of a given joint in a specific direction in relation to the adjacent bone. This technique aims to restore the restricted movement of the joint in question.
Study NCT01971983 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Individuals in this group received a sham intervention type, in order to simulate an intervention.
Study NCT01565044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor training
Description: Subject will perform prehension exercises on an automated table. After the initiation of the arm movement, the target to be grasped is programmed to move in order to stimulate automatic motricity.
Study NCT01565044 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: motor training
Description: Subject will perform prehension exercises on an automated table. After the initiation of the arm movement, the target to be grasped will remain static in order to involve intentional motricity.
Study NCT03405805 — intervention group
Intervention type: BIOLOGICAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Description: Vaccination with PCV13